BioInvent International AB at Jefferies Healthcare Conference Transcript
Hi everyone, my name is Matt Galle, I'm part of the Jefferies healthcare banking team. It's my pleasure to welcome you to the Jefferies Global Healthcare Conference. With us today we have Martin Welschof, part of BioInvent, CEO of BioInvent, here to give you a presentation. I'm going to turn it over to him. Thank you.
Thank you, Matt. And welcome, everybody. So this is our forward-looking statement and I will start with a quick snapshot of BioInvent.
So at BioInvent we are translating cancer biology into innovative immuno-oncology therapies and we are actually pushing ahead with a broad clinical portfolio, currently having five clinical programs running, soon six. And all these programs have been generated in-house since we are quite an integrated company. So we have a research engine that discovers targets and antibodies, we have our own manufacturing in-house, we can do up to 1,000 liter GMP, and obviously clinical development.
The technology that we use for
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |